Medicare Enrolled
Dr. Mukund Shah, M.D.
Hematology & Oncology · Palmdale, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Mukund Shah is a hematology & oncology specialist in Palmdale, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Shah performed 13,581 Medicare services across 1,163 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shah received a total of $4,391 from 53 pharmaceutical and/or device companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 27% volume in CA
$4,391 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,581
Medicare services
Top 27% in CA for hematology & oncology
1,163
Unique beneficiaries
$33
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~715 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,681 | $18 | $28 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,410 | $0 | $4 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,601 | $101 | $175 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,390 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
454 | $152 | $250 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
428 | $27 | $50 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
342 | $6 | $18 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
340 | $121 | $250 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
209 | $12 | $30 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
207 | $52 | $75 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
206 | $18 | $50 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 195 | $134 | $267 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
164 | $13 | $40 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
130 | $32 | $76 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
125 | $59 | $120 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
111 | $1 | $3 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
87 | $60 | $100 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
83 | $68 | $150 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
81 | $1 | $10 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
77 | $26 | $75 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
74 | $1 | $10 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
55 | $125 | $200 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
42 | $1 | $4 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
41 | $28 | $100 |
| New patient office visit, complex (60-74 min) | 29 | $167 | $303 |
| Heparin sodium injection, per 1000 units An injection of heparin sodium, a blood thinner, administered in units of 1000. |
19 | $0 | $0 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.9% high complexity
69.9% medium
20.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,391
Total received (2018-2024)
Avg $627/year across 7 years
Top 45% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
53
Companies
208
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,240 (96.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$151 (3.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$999
2023
$1,084
2022
$62
2021
$130
2020
$254
2019
$1,128
2018
$734
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$112
Janssen Biotech, Inc.
$91
Merck Sharp & Dohme LLC
$78
Novartis Pharmaceuticals Corporation
$72
EMD Serono, Inc.
$59
Tempus AI, Inc
$57
TerSera Therapeutics LLC
$56
Sumitomo Pharma America, Inc.
$52
PFIZER INC.
$42
Karyopharm Therapeutics Inc.
$38
SOBI, INC
$33
Regeneron Healthcare Solutions, Inc.
$32
Blue Earth Diagnostics Limited
$26
TAIHO ONCOLOGY, INC.
$25
Incyte Corporation
$25
GlaxoSmithKline, LLC.
$24
Takeda Pharmaceuticals U.S.A., Inc.
$22
Genentech USA, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$21
Legend Biotech USA Inc.
$21
ACCORD HEALTHCARE, INC.
$21
SpringWorks Therapeutics, Inc.
$21
Agios Pharmaceuticals, Inc.
$20
Astellas Pharma US Inc
$14
Blueprint Medicines Corporation
$14
Top 3 companies account for 28.2% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$714
PFIZER INC.
$351
Novartis Pharmaceuticals Corporation
$266
Astellas Pharma US Inc
$222
E.R. Squibb & Sons, L.L.C.
$190
AstraZeneca Pharmaceuticals LP
$183
Incyte Corporation
$175
Amgen Inc.
$168
Janssen Biotech, Inc.
$168
EMD Serono, Inc.
$141
Regeneron Healthcare Solutions, Inc.
$141
Merck Sharp & Dohme LLC
$122
TerSera Therapeutics LLC
$111
Merck Sharp & Dohme Corporation
$109
Celgene Corporation
$98
Gilead Sciences, Inc.
$77
Takeda Pharmaceuticals U.S.A., Inc.
$70
Foundation Medicine, Inc.
$69
Eisai Inc.
$66
TESARO, Inc.
$63
Tempus AI, Inc
$57
Sumitomo Pharma America, Inc.
$52
GlaxoSmithKline, LLC.
$46
ACCORD HEALTHCARE, INC.
$45
Rigel Pharmaceuticals, Inc.
$41
Karyopharm Therapeutics Inc.
$38
AbbVie Inc.
$37
Exelixis Inc.
$35
SOBI, INC
$33
Bayer Healthcare Pharmaceuticals Inc.
$32
MEDIVATION FIELD SOLUTIONS LLC
$28
Blue Earth Diagnostics Limited
$26
TAIHO ONCOLOGY, INC.
$25
Jazz Pharmaceuticals Inc.
$25
Lilly USA, LLC
$24
Bayer HealthCare Pharmaceuticals Inc.
$24
MorphoSys, US Inc.
$24
GENZYME CORPORATION
$22
PUMA BIOTECHNOLOGY, INC.
$21
Legend Biotech USA Inc.
$21
AbbVie, Inc.
$21
Puma Biotechnology, Inc.
$21
SpringWorks Therapeutics, Inc.
$21
Kite Pharma, Inc.
$20
EISAI INC.
$20
Agios Pharmaceuticals, Inc.
$20
Taiho Oncology, Inc.
$18
EUSA Pharma (US) LLC
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
INSYS Therapeutics Inc
$16
Tolmar, Inc.
$15
Blueprint Medicines Corporation
$14
Octapharma USA, Inc.
$13
Top 3 companies account for 30.3% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ALIMTA · AYVAKIT · Abraxane · Avastin · BAVENCIO · BESPONSA · Bavencio · CABOMETYX · CAMCEVI · Columvi · DARZALEX · DOPTELET · ELIGARD · ELIQUIS · EMPLICITI · ENHERTU · EVENITY · Erleada · FOUNDATIONONE · FRUZAQLA · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMFINZI · INLYTA · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUPRON DEPOT · LYNPARZA · Lenvima · Lonsurf · Lupron Depot · MONJUVI · MYLOTARG · Nerlynx · Nubeqa · OCTAGAM · OGSIVEO · OPDIVO · ORGOVYX · OXBRYTA · PIQRAY · POSLUMA · PROMACTA · PYRUKYND · Perjeta · Pomalyst · Quzyttir · RYBREVANT · RYDAPT · Revlimid · SCEMBLIX · SUTENT · SYNDROS · Stivarga · Sylvant · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · Tavalisse · Trodelvy · Venclexta · XALKORI · XPOVIO · XTANDI · Xermelo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
18
Per 100K population
0.2
County median income
$87,760
Nearest hospital
ANTELOPE VALLEY HOSPITAL
9.8 mi
9.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shah is a clinical cardiology specialist, with above-average Medicare volume (top 27% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Shah performed 4,681 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $4,391 from 53 companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other hematology & oncology specialists in Palmdale?
Dr. Shah's average Medicare payment per service is $33. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Palmdale
Browse hematology & oncology specialists in Palmdale ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology